The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Open accessAbstract
Acquired resistance to EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs) is inevitable in metastatic EGFR-mutant lung cancers. Here, we modeled disease progression using EGFR-mutant human tumor cell lines. Although five of six models displayed alterations already found in humans, one harbored an unexpected secondary NRAS Q61K mutation; resistant cells were sensitive to concurrent EGFR and MEK inhibition but to neither alone. Prompted by this finding and because RAS/RAF/MEK mutations are known mediators of acquired resistance in other solid tumors (colon cancers, gastrointestinal stromal tumors, and melanomas) responsive to targeted therapies, we analyzed the frequency of secondary KRAS/NRAS/BRAF/MEK1 gene mutations in the largest collection to date of lung cancers with acquired resistance to EGFR TKIs. No recurrent NRAS, KRAS, or MEK1 mutations were found in 212, 195, or 146 patient samples, respectively, but 2 of 195 (1%) were found to have mutations in BRAF (G469A and V600E). Ectopic expression of mutant NRAS or BRAF in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor. Collectively, these positive and negative results provide deeper insight into mechanisms of acquired resistance to EGFR TKIs in lung cancer and inform ongoing clinical trials designed to overcome resistance. In the context of emerging knowledge about mechanisms of acquired resistance to targeted therapies in various cancers, our data highlight the notion that, even though solid tumors share common signaling cascades, mediators of acquired resistance must be elucidated for each disease separately in the context of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to reactivation of PI3K, re-activation of ERK signaling can promote resistance to EGFR inhibitors as evidenced by the finding of a BRAF mutation in an EGFR mutant lung cancer with acquired resistance (Ohashi et al., 2012).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Ohashi et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationShigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation
Research works printed but not linked: 4
- 10.1371/journal.pmed.0020073 · DOI · Paper page
- 10.1126/scitranslmed.3002003 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-0714 · DOI
- 10.1242/dmm.003681 · DOI
Cited by
Sorted by citations
Items 401–445 of 445
Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
Genomic Applications in Pulmonary Malignancies
Büttner, R., Heydt, C., & Merkelbach‐Bruse, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_27 · Cited by 1
Genomic Applications in Pulmonary Malignancies
Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1
Haro, A., Kuramitsu, E., YAMAMOTO, I., & Fukuyama, Y. (2016) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2016.10.076 · Cited by 1
Tian, H., Zhang, X., Wang, Z., Yang, J., Guo, W., Chen, Z., & Wu, Y.-L. L. C. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.207478 · Cited by 1
Self-citationCirculating Cell-Free Tumor DNA in the Management of Double Primary Tumors
Dudnik, E., Twito, T., Faull, I., Dvir, A., Soussan‐Gutman, L., Purim, O., & Lanman, R. B. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00238 · Cited by 1
Tian, Y., Ma, Y., Wu, S., Zhang, T., Li, Z., Wang, G., & Zhang, J. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.07.017 · Cited by 1
BRAF: Novel Therapies for an Emerging Target
Myall, N. J., & Padda, S. K. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_4 · Cited by 1
Munoz, J. L. (2016) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
The reality of complexity: concomitant genomic alterations in patients with EGFR mutations
Cardona, A. F., Zatarain-Barrón, Z. L., Rojas, L., & Arrieta, O. G. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.136 · Cited by 1
The mechanisms of the anti-tumour effect of inactivating ICMT in BRAF-induced cancer
Shkoukani, S. (2013) · Chalmers Publication Library (Chalmers University of Technology)
Identifying Actionable Targets in Cancer Patients
Uehling, D., Dancey, J. E., Brown, A. M. K., McPherson, J. D., & Al‐awar, R. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch07
Other novel molecular targets in non-small cell lung cancer: It's not all about EGFR
Cruikshank, R. P., & Hughes, B. G. M. (2013) · Cancer Forum
Overcoming EGFR-TKI Resistance
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_4
Cappuzzo, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-20741-4_3
Personalized Management of Lung Cancer
Komaki, R. R. (2013) · doi:10.2217/9781780842165
RAS‐RAF‐MEK Pathway: Aberrations and Therapeutic Possibilities
Javier, M., & Jankú, F. (2015) · Wiley eBooks · doi:10.1002/9781118468678.ch31
Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer
Mirone, G., Perna, S., & Marfè, G. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46091-8_2
Wu, K. H. (2016) · Human Biology
Mechanisms of IKBKE Activation in Cancer
Challa, S. (2017) · Digital Commons - University of South Florida (University of South Florida)
Pharmacogenomics in Lung Cancer Treatment
Kılıç, N., & Cansaran‐Duman, D. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2017.21703
Bagán, S. G. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Investigations into how best to target FGFR2 mutant endometrial cancer
Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437
Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Marcoux, N., & Sequist, L. V. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00007-9
Self-citationTBHEB 2017-2 Vol 74 Full Printed Journal
Ercömart, U. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2017.82356
Liu, Z. (2018) · ThinkTech (Texas Tech University)
Rebiopsy in IV stage non-small-cell lung cancer patients after systemic therapy
Yudin, D. I., Anteev, A. A., Тодорович, М. Д., Сергеевич, А. М., & Лактионов, К. К. (2016) · Russian Journal of Oncology · doi:10.18821/1028-9984-2016-21-4-179-185
Тодорович, М. Д., Лактионова, Л. В., Реутова, Е. В., & Иванович, Ю. Д. (2020) · Естественные и Технические Науки · doi:10.37882/2223-2966.2020.09.24
Apoptosis signaling in EGFR inhibitor resistance in NSCLC
Aka, Y., Karakaş, B., & Kütük, Ö. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00001-2
Ghotane, R. B., Charde, M. S., Chakole, R. D., Bhandari, S. V., & Shimpi, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7082373/v1
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M. L., Yeap, J. W., & Matawali, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_258
Giri, S., Selvadurai, B.-R., Nieves, A. S., Gupta, N., Lindzen, M., Chatterjee, R., Genna, A., Daele, M. V., Ramesh-Kumar, D., Zerbib, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.681972
Genomic Biomarker Discovery for Drug Sensitivity Using Omics Data
Wu, J., & Fang, K. (2025) · Computational Molecular Biology · doi:10.5376/cmb.2025.15.0013
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Drug resistance in cancer radiotherapy: From mechanisms to overcoming strategies
Chen, Y., Cai, C., Xu, X.-C., Yang, Z., Li, J., Pan, Q., Wang, L., Luo, W., Chen, Z., Zeng, L., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108380
Self-citationTherapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer
Facchinetti, F., Friboulet, L., Liao, L., Peroni, M., Nakazawa, S., Zullo, L., Aldea, M., Pecci, F., Makarem, M., Alonso-García, I., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.08.004
Prime editing reveals the resistance landscape of EGFR tyrosine kinase domain variants
Lee, J., Park, B., Kim, S., Kim, S., & Kim, Y. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01726-1
Giri, S., Selvadurai, B. R., Gupta, N., Nieves, A. S., Genna, A., Lindzen, M., Chatterjee, R., Daele, M. V., Ramesh-Kumar, D., Zerbib, M., et al. (2026) · Advanced Science · doi:10.1002/advs.78290
Metadata
- Authors
- Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., Aoe, K., Toyooka, S., Kiura, K., Fernandez-Cuesta, L., Fidias, P., Yang, J. C.-H., Miller, V. A., Riely, G. J., Kris, M. G., Engelman, J. A., Vnencak-Jones, C. L., Dias-Santagata, D., Ladanyi, M., & Pao, W.
- Affiliations
- Vanderbilt University (US)
- Harvard University (US)
- Department of Pathology,
- Catalan Institute of Oncology, Universitat Autonoma de Barcelona and Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain;
- Cornell University (US)
- Anti-Tumor Assessment Core Facility, and
- Okayama University Hospital (JP)
- National Sanyo Hospital (JP)
- Okayama University (JP)
- Max Planck Institute for Neurological Research with Klaus Joachim Zülch Laboratories of the Max Planck Society and the Medical Faculty, Cologne 50931, Germany;
- National Taiwan University (TW)
- Memorial Sloan Kettering Cancer Center (US)
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232; and
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2012-07-06
- Volume
- 109
- Issue
- 31
- Pages
- E2127-33
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3411967
- OpenAlex
- W2096540669
- Cited by
- 441
- References
- 42
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10 · 2023: 13 · 2022: 16 · 2021: 28 · 2020: 27 · 2019: 23 · 2018: 51 · 2017: 50 · 2016: 54 · 2015: 60 · 2014: 45 · 2013: 40 · 2012: 4
- FWCI
- 38.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Celgene
- Clovis Oncology
- Agios Pharmaceuticals
- Symphogen
- U.S. Public Health Service (1R21-156000)
- Foundation Medicine
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, CA90949, U54CA143798, P50CA090949, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- EGFR tyrosine kinase inhibitors, acquired drug resistance, EGFR-mutant lung cancer, BRAF mutation, NRAS Q61K, KRAS mutation, MEK1 mutations, Ras/Raf/MEK signaling, MEK inhibitor combination, secondary mutations, metastatic lung cancer
- MeSH terms
- Clinical Trials as Topic, Female, Humans, Lung Neoplasms, Male, Proto-Oncogene Proteins, Proto-Oncogene Proteins p21(ras), ras Proteins, Drug Resistance, Neoplasm, Amino Acid Substitution, Mutation, Missense, Cell Line, Tumor, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
